- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BridgeBio Pharma Inc (BBIO)
The BridgeBio Pharma share price today is 79.86, view NASDAQ BBIO stock exchange data. Track the latest BridgeBio Pharma share price with real-time updates on BBIO stock performance including market cap, day range, 52-week range and dividend yield. Access BBIO charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.60
80.56
52 wk Range
46.81
93.42
BBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.6080.56
52 wk Range
46.8193.42
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BBIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
108.43
Upside
+35.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
19 Buy
3 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 108.43
(+35.77% Upside)
BridgeBio Pharma Inc SWOT Analysis
Commercial Success | Attruby generated $146M in Q4, driving 355% revenue growth and approximately 1,200 new prescriptions since mid-January, exceeding expectations |
Analyst Perspectives | Price targets range from $88 to $157, averaging $118, reflecting varied views on profitability timeline and competitive positioning |
Pipeline Potential | Discover how encaleret, infigratinib, and BBP-418 each target billion-dollar rare disease markets with launches anticipated through 2027 |
Patent Challenges | Examine intellectual property uncertainties following Pfizer's European patent withdrawal and potential generic tafamidis competition impact |
BridgeBio Pharma Inc Earnings Call Summary for Q2/2026
- BridgeBio Q2 revenue hit $243.7M, beating estimates by 10.66% and more than doubling year-over-year, driven by Attruby's 211% surge to $222.4M.
- Operating loss narrowed to $107.1M from $134.3M despite higher expenses, as $1B preferred equity financing boosted pro forma cash to $1.7B.
- Company missed EPS forecast by 30% at -$0.78 vs. -$0.60 expected, reflecting heavy investment in commercial expansion and pipeline development.
- Management expects Attruby to reach blockbuster status in 2026 with path to breakeven profitability by late 2026-2027 as revenue growth accelerates.
- Three pipeline products face FDA decisions through mid-2027, including BBP-418 (Nov 2026), encaleret (May 2027), and infigratinib (mid-2027).
Last Updated: 11-08-2026, 03:32 am
Read Full TranscriptEarnings
Latest Release
10-08-2026
EPS / Forecast
-0.78 / -0.60
Revenue / Forecast
243.67M / 220.19M
Compare BBIO to Peers and Sector
Metrics to compare | BBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.6x | −1.5x | −0.4x | |
PEG Ratio | −1.75 | −0.14 | 0.00 | |
Price/Book | −6.2x | 2.0x | 2.6x | |
Price / LTM Sales | 21.9x | 7.4x | 3.1x | |
Upside (Analyst Target) | 35.2% | 176.4% | 47.8% | |
Fair Value Upside | Unlock | 20.0% | 6.2% | Unlock |
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the BridgeBio Pharma (BBIO) Share Price Today?
The BridgeBio Pharma share price today is 79.86.
What is the current BridgeBio Pharma (BBIO) share price and day range?
As of 15-08-2026, the BridgeBio Pharma share price is 79.86, with a previous close of 81.21. The share price has ranged from 78.60 to 80.56 today, while the 52-week range spans from 46.81 to 93.42.
What Is the BridgeBio Pharma Market Cap?
As of today, BridgeBio Pharma market cap is 15.88B.
What Is the BridgeBio Pharma (BBIO) Share Price Target?
The average 12-month share price target for BridgeBio Pharma is 108.43, with a high estimate of 157 and a low estimate of 80. 19 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +35.77% Upside potential.
What Is BridgeBio Pharma's Earnings Per Share (TTM)?
The BridgeBio Pharma EPS (TTM) is -3.57.
When Is the Next BridgeBio Pharma Earnings Date?
BridgeBio Pharma will release its next earnings report on 29-10-2026.
From a Technical Analysis Perspective, Is BBIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does BridgeBio Pharma Trade On?
BridgeBio Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BridgeBio Pharma?
The stock symbol for BridgeBio Pharma is "BBIO."
How Many Times Has BridgeBio Pharma Stock Split?
BridgeBio Pharma has split 0 times.
How Many Employees Does BridgeBio Pharma Have?
BridgeBio Pharma has 1001 employees.
What Is the BBIO Premarket Price?
BBIO's last pre-market stock price is 79.99. The pre-market share volume is 36,570.00, and the stock has changed by -1.22, or -1.50%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.